Science Links Japan | CBDCA, Etoposide and Epirubicin High-dose Combination Chemotherapy Supported by Peripheral Blood Stem Cell Transplantation(PBSCT) in Metastatic Breast Cancer.

CBDCA, Etoposide and Epirubicin High-dose Combination Chemotherapy Supported by Peripheral Blood Stem Cell Transplantation(PBSCT) in Metastatic Breast Cancer.

Accession number;99A0203857

Title;CBDCA, Etoposide and Epirubicin High-dose Combination Chemotherapy Supported by Peripheral Blood Stem Cell Transplantation(PBSCT) in Metastatic Breast Cancer.

Author; SUWATA JUNJI (Saitama Medical School, General Medical Center) TAKADA SHIN (Saitama Medical School, General Medical Center) ISHIZUKA NAOKI (Saitama Medical School, General Medical Center) MURATA NOBUO (Saitama Medical School, General Medical Center) IDEZUKI YASUO (Saitama Medical School, General Medical Center) KOBAYASHI MASAYUKI (Saitama Medical School, General Medical Center)

Journal Title;Japanese Journal of Cancer and Chemotherapy

Journal Code:Z0938A

ISSN:0385-0684

VOL.26;NO.1;PAGE.83-88(1999)

Figure&Table&Reference;TBL.3, REF.20

Pub. Country;Japan

Language;Japanese

Abstract;Six metastatic breast cancer patients, including one brain metastasis, one lung metastasis, three local recurrences and one bone metastasis, underwent multidrug chemotherapy with CBDCA, Etoposide(ETP) and Epirubicin(EPI). Each patient received two courses of PBSC mobilization chemotherapies and subsequently received high-dose chemotherapies for at least two courses. CBDCA AUC 4, ETP 300mg/m2 and EPI 40mg/m2 were administered intravenously as a PBSC mobilization chemotherapy, and high-dose chemotherapies were performed under the regimen of CBDCA AUC 8, ETP 900mg/m2 and EPI 60mg/m2. Severe bone marrow suppression due to high-dose chemotherapies was off sct by autologous peripheral blood stem cell transplantation(PBSCT). The PBSC mobilization chemotherapies resulted in one CR, three PR, one NC and one PD in the six patients. The PD patient died before high-dose chemotherapy. Consequently, the remaining five patients received the high-dose chemotherapies, which achieved three CR, one PR and one PD in the five patients. The response rate of high-dose chemotherapy was 80% (4/5 cases). In overall outcome, three patients have continued 16, 12 and 10 months tumor-free survival, and three patients died of cancer progression. High-dose chemotherapy with CBDCA, ETP and EPI has led to increased CR rates in metastatic breast cancer, and such therapy has desirable effect on the patient's prognosis. (author abst.)

Related Articles;